Type III CRISPR-Cas prokaryotic immune systems provide anti-viral and anti-plasmid immunity via a dual mechanism of RNA and DNA destruction. Upon target RNA interaction, Type III crRNP effector complexes become activated to cleave both target RNA (via Cas7) and target DNA (via Cas10). Moreover, trans-acting endoribonucleases, Csx1 or Csm6, can promote the Type III immune response by destroying both invader and host RNAs. Here, we characterize how the RNase and DNase activities associated with Type III-B immunity in Pyrococcus furiosus (Pfu) are regulated by target RNA features and second messenger signaling events. In vivo mutational analyses reveal that either the DNase activity of Cas10 or the RNase activity of Csx1 can effectively direct...
CRISPR systems are widespread in the prokaryotic world, providing adaptive immunity against mobile g...
The CRISPR system for prokaryotic adaptive immunity provides RNA-mediated protection from viruses an...
Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) second messengers in response to vira...
Funding: National Institutes of Health (NIH) [R35GM118160 to M.P.T., R01GM097330 to S.B. and 1F31GM1...
The type III CRISPR-Cas systems provide immunity against invading nucleic acids through the coordina...
CRISPR-Cas systems provide prokaryotes with RNA-based adaptive immunity against viruses and plasmids...
<p>CRISPR-Cas systems provide prokaryotes with RNA-based adaptive immunity against viruses and plasm...
Antiviral defence systems that exhibit high specificity, such as prokaryotic CRISPR-Cas, are widely ...
CRISPR-Cas systems provide an adaptive defence against foreign nucleic acids guided by small RNAs (c...
In many prokaryotes, type III clustered regularly interspaced short palindromic repeat (CRISPR)-CRIS...
Prokaryotic CRISPR-Cas systems provide an RNA-guided mechanism for genome defense against mobile gen...
Immunity against viruses and plasmids provided byCRISPR-Cas systems relies on a ribonucleoproteineff...
The type I-F CRISPR adaptive immune system in Pseudomonas aeruginosa (PA14) consists of two CRISPR l...
Type I CRISPR-Cas systems typically rely on a two-step process to degrade DNA. First, an RNA-guided ...
In many prokaryotes, type III clustered regularly interspaced short palindromic repeat (CRISPR)-CRIS...
CRISPR systems are widespread in the prokaryotic world, providing adaptive immunity against mobile g...
The CRISPR system for prokaryotic adaptive immunity provides RNA-mediated protection from viruses an...
Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) second messengers in response to vira...
Funding: National Institutes of Health (NIH) [R35GM118160 to M.P.T., R01GM097330 to S.B. and 1F31GM1...
The type III CRISPR-Cas systems provide immunity against invading nucleic acids through the coordina...
CRISPR-Cas systems provide prokaryotes with RNA-based adaptive immunity against viruses and plasmids...
<p>CRISPR-Cas systems provide prokaryotes with RNA-based adaptive immunity against viruses and plasm...
Antiviral defence systems that exhibit high specificity, such as prokaryotic CRISPR-Cas, are widely ...
CRISPR-Cas systems provide an adaptive defence against foreign nucleic acids guided by small RNAs (c...
In many prokaryotes, type III clustered regularly interspaced short palindromic repeat (CRISPR)-CRIS...
Prokaryotic CRISPR-Cas systems provide an RNA-guided mechanism for genome defense against mobile gen...
Immunity against viruses and plasmids provided byCRISPR-Cas systems relies on a ribonucleoproteineff...
The type I-F CRISPR adaptive immune system in Pseudomonas aeruginosa (PA14) consists of two CRISPR l...
Type I CRISPR-Cas systems typically rely on a two-step process to degrade DNA. First, an RNA-guided ...
In many prokaryotes, type III clustered regularly interspaced short palindromic repeat (CRISPR)-CRIS...
CRISPR systems are widespread in the prokaryotic world, providing adaptive immunity against mobile g...
The CRISPR system for prokaryotic adaptive immunity provides RNA-mediated protection from viruses an...
Type III CRISPR systems synthesise cyclic oligoadenylate (cOA) second messengers in response to vira...